Chronic myelomonocytic leukemia

Rare Hematological Malignancies

Volumn , Issue , 2008, Pages 107-132

  Beran, Miloslav ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; HUMAN; REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC;

EID: 77951020983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-73744-7_5     Document Type: Chapter

References (144)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
2. Bennett JM, Catovsky D, Daniel TM, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994;87:746-54.
3. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
4. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-849.
5. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004;45:1311-1318.
6. Vardiman JW, Harris NL, Banning R. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
7. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995;86:3542-3552.
8. Beran M, Wen S, Shen Y, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M. D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007;48:1150-1160.
9. Fenaux P, Beuscart R, Lai JL, et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988;6:1417-1424.
10. Felzmann T, Gisslinger H, Krieger O, et al. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. Br J Haematol 1993;84:428-435.
11. Beran M, Shen Y, Onida F, et al. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma 2006;47:417-423
12. Tefferi A, Elliot MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc 2006;81:553-563.
13. Galton DA. Hematological differences between chronic granulocytic leukemia, atypical chronic myeloid leukemia and chronic myelomonocytic leukemia. Leuk Lymphoma 1992;7:343-350.
14. Nosslinger T, Reisner R, Gruner H, et al. Dysplastic versus proliferative CMML: a retrospective analysis of 91 patients from a single institution. Leuk Res 2001;25:741-747.
15. Germing U, Gattermann N, Minning H, et al. Problems in the classification of CMML: dysplastic versus proliferative type. Leuk Res 1998;22:871-878.
16. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 2004;3:218-226.
17. Voglova J, Chrobak L, Neuwirtova R, et al. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia: distinct subgroups or two stages of the same disease? Leuk Res 2001;25:493-499.
18. Cervera J, Sanz GF, Vallespi T, et al. Does WBC count really define two different subtypes of chronic myelomonocytic leukemia (CMML) ? Analysis of a series of 119 patients (Abstract). Leukemia Res 1997;21:7.
19. Rigolin GM, Cuneo A, Roberti MG, et al. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica 1997;82:25-30.
20. Cuneo A, Tomasi P, Ferrari L, et al. Cytogenetic analysis of different cellular populations in chronic myelomonocytic leukemia. Cancer Genet Cytogenet 1989;37:29-37.
21. Fugazza G, Bruzzone R, Dejana AM, et al. Cytogenetic clonality in chronic myelomonocytic leukemia studied with fluorescence in situ hybridization. Leukemia 1995;9:109-114.
22. Geissler K, Ohler L, Fodinger M, et al. Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. J Exp Med 1996;184:1377-1384.
23. Everson MP, Brown CB, Lilly MB. Interleukin-6 and granulocyte-macrophage colonystimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood 1989;74:1472-1476.
24. Ramshaw HS, Bardy PG, Lee MA, et al. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol 2002;30:1124-1131.
25. Dresh C, Faille A, Poirier O. Bone marrow cell kinetic and culture in chronic and subacute myelomonocytic leukemia. Physiopathological interpretation and prognostic importance. Leuk Res 1979;4:129-133.
26. Yuo A, Miyazono K, Takaku F. Characterization of granulocyte-macrophage colony formation in chronic myelomonocytic leukemia: a comparative study with other myelodysplastic and myeloproliferative disorders. Jpn J Cancer Res 1990;81:820-826.
27. Cambier N, Baruchel A, Schlageter MH, et al. Chronic myelomonocytic leukemia: from biology to therapy. Hematol Cell Ther 1997;39:41-48.
28. Oscier DG, Worsley A, Darlow S, et al. Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score. Leuk Res 1989;13:833-839.
29. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-187.
30. Emanuel PD, Bates LJ, Castleberry RP, et al. Selective hypersensitivity to granulocytemacrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991;77:925-929.
31. Shanon KM, LeBeau MM, Largaespada DA, et al. Modelling myeloid leukemia tumor suppressor gene inactivation in the mouse. Am J Med Genet 1999;89:14-22.
32. Le DT, Shannon KM. Ras processing as a therapeutic target in hematological malignancies. Curr Opin Hematol 2002;9:308-315.
33. Akashi K, Shibuya T, Harada M, et al. Interleukine 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells. J Clin Invest 1991:88;223-230.
34. Everson MP, Brown CB, Lilly MB. Interleukin-6 and granulocyte-macrophage colonystimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood 1989;74:1472-1476.
35. Berkowicz M, Rosner E, Rechavi G, et al. Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12): a new association. Cancer Genet Cytogenet 1991;51:277-278.
36. Wessels JW, Fibbe WE, van der Keur D, et al. t (5;12) (q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer Genet Cytogenet 1993;65:7-11.
37. Golub TR, Barker GF, Lovett M, et al. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation. Cell 1994;77:307-316.
38. Carrol M, Tomasson MH, Barker GF, et al. The TEL/platelet-derived growth factor beta receptor (PDGFbeta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFbeta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996;93:14, 845-14, 850.
39. Abe A, Emi N, Tanimoto M, et al. Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 1997;90:4271-4277.
40. Ross TS, Bernard OA, Berger R, et al.: Fusion of Huntingtin interacting protein 1 to plateletderived growth factor beta receptor (PDGFbR) in chronic myelomonocytic leukemia with t (5;7) (q33;q11.2). Blood 1998;91:4419-4426.
41. Kulkermi S, Heath C, Parker S, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t (5;10) (q33;q21). Cancer Res 2000;60:3592-3598.
42. Schwaller J, Anastasiadou E, Cain D, et al. H4 (D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t (5;10) (q33;q22). Blood 2001;97:3910-3918.
43. Magnusson MK, Meade KE, Brown KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001;98:2518-2525.
44. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t (1;5) (q23;q33) in a myeloproliferative disorder associated with eosinophilia: Involvement of PDGFRbeta and response to imatinib. Blood 2003;102:4187-4190.
45. Vizmanos JL, Novo FJ, Roman JP, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRbeta in a patient with a t (5;14) (q33;q24) and in an imatinib-responsive myeloproliferative disorder. Cancer Res 2004;64:2673-2676.
46. Moreiro C, Acquila M, Rosanda C, et al. HCMOGT-1 is a novel fusion partner to PDGFRbeta in juvenile myelomonocytic leukemia with t (5;17) (q33;p11.2). Cancer Res 2004;64:2649-2651.
47. Levine RL, Wadleigh M, Sternberg DW, et al. KIAA1509 is a novel PDGFRbeta fusion partner in imatinib-responsive myeloproliferative disease associated with a t (5;14) (q33;q32). Leukemia 2005;19:27-30.
48. Grant FH, Burgstaller S, Kuhr T, et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t (5;15) (q22;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004;64:7216-7219.
49. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002;16:1207-1212.
50. Baxter EJ, Hochhaus A, Bolufer P, et al. The t (4;22) (q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRalpha. Hum Mol Genet 2002;11:1391-1397.
51. JAK2 as a result of t (9;12) in a lymphoid and t (9;15;12) in a myeloid leukemia. Blood 1997;90:2535-2540.
52. Reiter A, Walz C, Watmore A, et al. The t (8;9) (p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-2667.
53. Fenaux P, Jouet JP, Zandecki M, et al. Chronic and subacute myelomonocytic leukemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol. 1987;65:101-106.
54. Groupe Francais de Cytogenetique Hematologique. Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 1986;21:11-30.
55. Groupe Francais de Cytogenetique Hematologique. Chronic myelomonocytic leukemia: single entity or heterogenous disorder? A prospective multicenter study of 100 patients. Cancer Genet Cytogenet 1991;55:57-65.
56. Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000;108:346-356.
57. Gunby RH, Camzzaniga G, Tassi E et al. Sensitivity to imatinib but low frequency of TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica 2003;88:408-415.
58. Onida F, Glassman A, Estey E et al. Cytogenetics of CMML and Ph-negative CML: a retrospective analysis and comparison with MDS. Blood 1999;84(Suppl 1):273.
59. Onida F, Ball G, Kantarjian HM, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002;95:1673-1684.
60. Frohling S, Scholl C, Gilliland DG, et al. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-6295.
61. Tsurumi S, Nakamura Y, Maki K, et al. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol 2002;71:131-133.
62. Janssen JW, Steenvoorden AC, Lyons J, et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA 1987;84:9228-9232.
63. Padua RA, Carter G, Hughes D, et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 1988;2:503-510.
64. Collins SJ, Howard M, Andrews DF, et al. Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. Blood 1989;73:1028-1032.
65. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 1990, 76:1214-1219.
66. Onida F, Kantarjian HM, Ball G, et al. The dysplastic versus proliferative classification dilemma of chronic myelomonocytic leukemia: a retrospective single institution analysis of 273 patients. Blood 2001;98:11(Suppl 1):2607.
67. Onida F, Gatto S, Scappini B, et al. Significance of ras point mutations for prognosis and response to treatment in chronic myelomonocytic leukemia: analysis of 112 patients. Proc Am Soc Clin Oncol 2002;20:abstr 1048.
68. Shih LY, Huang CF, Wang PN, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004;18:466-475.
69. Ricci C, Onida F, Fermo E, et al. Acquisition of RAS mutations contributes to progression of CMML from the dysplastic to the proliferative variant. Abstract, AACR 2007; in press.
70. Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 1999;89:14-22.
71. Shannon K M, LeBeau M M, Largaespada DA, et al. Modelling myeloid leukemia tumor suppressor gene inactivation in the mouse. Semin Cancer Biol 2001;11:191-200.
72. Lu D, Nounou R, Beran M, et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and RAS oncogene mutations in patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97:441-449.
73. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-150.
74. Tartaglia M, Niemeyer CM, Shannon KM, et al. SHP-2 and myeloid malignancies. Curr Opin Hematol 2004;11:44-50.
75. Loh ML, Martinelli S, Cordeddu V, et al. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 2005;29:459-462.
76. Johan MF, Bowen DT, Frew ME, et al. Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2004;124:843-844.
77. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
78. Levine RL, Loriaux M, Huntley BJP et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myelogenous leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377-3379.
79. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005;106:1207-1209.
80. Jelinek J, Oki Y, Gharibzan V, et al. JAK2 mutation 1849>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3373.
81. Parganas E, Wang D, Stravopodis D, et al. JAK2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-395.
82. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-665.
83. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-3080.
84. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
85. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-1759.
86. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res 2001;61:7233-7239.
87. Beran M, Luthra R, Kantarlian H, et al. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 2004;28:547-550.
88. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
89. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-4335.
90. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neopasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-586.
91. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Natl Rev Genet 2002;3:415-428.
92. Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002;87:1324-1341.
93. Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in earlystage patients. Eur J Haematol 2005;10:1-10.
94. Johan MF, Bowen DT, Frew ME, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2005;129:60-65.
95. Shang JW, Ming Y, Wen-Chien C. Clinical implication of SOC1 methylation in myelodysplastic syndrome. Br J Haematol 2006;135:317-323.
96. Tessema M, Langer F, Dingemann J, et al. Aberrant methylation and impaired expression of the p15 (INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003;17:910-918.
97. Worsley A, Oscier DG, Stevens J, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988;68:17-21.
98. Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-59.
99. Aul C, Gattersman N, Germing U, et al. Risk assessment in primary myelodysplastic syndromes: validation of the Dusseldorf score. Leukemia 1994;8:1906-1913.
100. Germing U, Strupp C, Aivado M, et al. New prognostic parameters for chronic myelomonocytic leukemia. Blood 2002;100:731-733.
101. Cox DR. Regression models and life tables (with discussion). J Stat Soc 1972;34:187-220.
102. Kerridge I, Spencer A, Azzi A, et al. Response to erythropoietin in chronic myelomonocytic leukaemia. Intern Med J 2001;31:371-2.
103. Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus vp16 in adult chronic myelomonocytic leukemia. Blood 1996;88:2480-2487.
104. Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996;88:2473-2479.
105. Beran M, O'Brien S, Thomas DA, et al. Phase I study of prolonged administration of oral topotecan in hematological malignancies. Clin Cancer Res 2003;9:4084-4091.
106. Cortes J, O'Brien S, Beran M, et al. Efficacy of topoisomerase I inhibitor 9-nitro-20-S campthotecin (9-NC, RFS 2000) in chronic myelomonocytic leukemia (CMML) and high-risk myelodysplastic syndromes (MDS) Blood 98;2001, 621a.
107. Raza M, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in ilongstanding refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-965.
108. Silverman LR, Holland JF, Demakos EP, et al. Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol 1994;68:A12.
109. Siverman LR, Demakos EP, Weinberg AS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):21-29.
110. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
111. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacytidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11:3604-3608.
112. Attadia V, Pinto A, Colombatti A. Stepwise induction of differentiation of the U937 cell line by 5, Aza-2'-deoxycitidine. Exp Hematol 1988;16:474-477.
113. Pinto A, Attadia V, Fusco A, et al. 5-Aza-2, -deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984;64:922-929.
114. Zagonel V, Lo Re G, Marotta G, et al. 5, -Aza-2, -deoxycitidine (Decitabine) induces trilineage response in unfavorable myelodysplastic syndrome. Leukemia 1993;7(Suppl 1);9-16.
115. Wijermans PW, Krulder JWM, Huijgens PC, et al. Continuous infusion of low dose 5-aza-2 deoxycitidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11:1-5.
116. Wijermans P, Lubbet M, Verhoef G, et al. Low-dose 5-ara-2-deoxycitidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-962.
117. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803.
118. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycitidine (decitabine) in hematopoeitic malignancies. Blood 2004;103:1635-1640.
119. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57.
120. Beran M, Estey E, O'Brien S, et al. Results of topotecan single agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 1998;31:521-531.
121. Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999;17:2819-2830.
122. Beran M, Onida F, Cortes JE, et al. Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia. Blood 2001;98:abstr 624a.
123. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90:4947-4952.
124. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
125. Pitini V, Arrigo C, Teti G, et al. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptpr involvement: a new case report. Haematologica 2003;88:ECR18.
126. Magnusson MK, Meade KE, Nakamura R, et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 2002;100:1088-1091.
127. Garcia JL, Font de Mora J, Hernandez JH, et al. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving platelet-derived growth factor receptor beta. lood 2003;102:2699-2700.
128. David M, Cross NCP, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusiongene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109:61-64.
129. Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003;97:2760-2766.
130. Raza A, Lisak L, Dutt D, et al. Gleevac (imatinib mesylate) in 16 patients with chronic myelomonocytic leukemia (CMMoL). Blood 2000;96(Suppl 1):abstr 4829.
131. Kurzrock R, Kantarjian H, Cortes JE, et al. Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome: clinical and biological activities in the phase I setting. Blood 2003;102:4527-4534.
132. ™ (farnesyl transferase inhibitor (FTI) R11577, Tipifarnib) in patients with myeloproliferative disorders (MPDs): preliminary results. Blood 2002;100:abstr 3153.
133. ™). Blood 2004;104:abstr 68.
134. ™) for the treatment of patients with myelodysplastic syndrome. Blood 2003;102:abstr 1531.
135. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-3369.
136. Seymour J, Cortes J. Chronic myelomonocytic leukemia. In: Talpaz M, Kantarjian H, editors. Medical management of chronic myelogenous leukemia. New York: Marcel Dekker; 1999. p/43-48.
137. Beran M. Management of chronic myelomonocytic leukemia and other rare myeloproliferative disorders. In: Sekeres M, editor. Clinical malignant hematology; 2007. p. 487-502.
138. Kroger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002;118:67-73.
139. Zang DY, Deeg HJ, Gooley T, et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000;110:217-222.
140. Mittal P, Saliba RM, Giralt SA, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004;33:1005-1009.
141. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997;15:566-573.
142. Alzea EP, Kim HT, Cutter C, et al. AML and MDS treated with nonmyeloablative stem cell transplantation: overall and progression-free survival comparable to myeloablative transplantation. Blood 2003;102:abstr 266.
143. Giralt S, Anagnastopoulos A, Shahjahauau M, et al. Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 2002;39:57-62.
144. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia with multilineage dysplasia using flufarabin, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004;104:1616-1623.